Kayoko Saito

Director & Professor

Tokyo Women's Medical University

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Kayoko Saito is a Director and Professor at Tokyo Women's Medical University in Japan. Her research primarily focuses on spinal muscular atrophy, including the safety and efficacy of treatments like risdiplam and onasemnogene abeparvovec. Recent publications include studies on the genomic analysis of the SMN1 gene and investigations into the epidemiology of spinal muscular atrophy in Japan.

Articles (12)

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (6)

Kazuki Obara

Lund University

SWEDEN

View details

Kenichi Fudeyasu

Hiroshima University Hospital

JAPAN

View details

Giovanni Baranello

Prof.

University College London

UNITED KINGDOM

View details

Hugh J. McMillan

McGill University

CANADA

View details

Michelle Farrar

Senior Lecturer, Paediatric Neurology

University of New South Wales

AUSTRALIA

View details

nathalie goemans

associate professor- Emeritus

Katholieke Universiteit Leuven

BELGIUM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kayoko Saito

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Safety of Risdiplam in Japanese Patients with Spinal Muscular Atrophy: A 12‑Month Interim Analysis of a Postmarketing Surveillance Study

Genomic analysis of the SMN1 gene region in patients with clinically diagnosed spinal muscular atrophy: a retrospective observational study

Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA)

Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)

Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial

Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial

Epidemiological investigation of spinal muscular atrophy in Japan

Precision cancer genome testing needs proficiency testing involving all stakeholders

Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial

Clinicopathologic Features of Oculopharyngodistal Myopathy with LRP12 CGG Repeat Expansions Compared with Other Oculopharyngodistal Myopathy Subtypes

Cybernic treatment with wearable cyborg Hybrid Assistive Limb (HAL) improves ambulatory function in patients with slowly progressive rare neuromuscular diseases: a multicentre, randomised, controlled crossover trial for efficacy and safety (NCY-3001)

Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy

Collaborators (6)

Kazuki Obara

Kenichi Fudeyasu

Giovanni Baranello

Hugh J. McMillan

Michelle Farrar

nathalie goemans

Make your next move.